NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024

202494 citationsJournal Article

Authors

Joyce F. Liu · Dana-Farber Brigham Cancer Center

Floor Backes · The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Joshua G. Cohen · City Of Hope National Medical Center

Rachel N. Grisham · Memorial Sloan Kettering Cancer Center

Charles A. Leath · University of Colorado Denver

Abstract

The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.

Topics & Keywords

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy Intraperitoneal and Appendiceal Malignancies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the National Comprehensive Cancer Network

Volume 22, Issue 8, pp. 512-519

DOI: 10.6004/jnccn.2024.0052

Field-Weighted Citation Impact: 49.98